AlphaCentric Advisors’s BioNTech BNTX Stock Holding History

AlphaCentric Advisors’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$583K	Buy	6,266 +650	+12%	+$61.2K	0.49%	73
2026 Q1	$499K	Buy	5,616 +305	+6%	+$31.3K	0.5%	60
2025 Q4	$506K	Buy	+5,311	New	+$535K	0.5%	62
2024 Q4	$168K	Buy	+1,474	New	+$168K	0.17%	133
2020 Q3	–	Sell	-550	Closed	-$37K	–	168
2020 Q2	$37K	Buy	+550	New	+$27.5K	0.02%	97

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

AlphaCentric Advisors's BNTX Position: Q2 2026 in Review

AlphaCentric Advisors increased its BioNTech (BNTX) stake by 12% in Q2 2026, buying an estimated $61.2K and bringing the position to 6,266 shares worth $583K. The position accounts for 0.49% of the portfolio, ranked #73.

AlphaCentric Advisors first reported a position in BNTX in Q2 2020 and has held it in 5 quarters since. 283 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

AlphaCentric Advisors held 6,266 shares of BioNTech worth $583K as of Q2 2026.
AlphaCentric Advisors bought 650 BioNTech shares in Q2 2026, an estimated $61.2K.
BioNTech made up 0.49% of AlphaCentric Advisors's portfolio in Q2 2026, its #73 holding.
AlphaCentric Advisors first reported a position in BioNTech in Q2 2020 and has held it in 5 quarters since.
283 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.